Edoxaban-d6

Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment[1][2][3].

Product Specifications

CAS Number

[1304701-57-2]

Product Name Alternative

DU-176-d6

UNSPSC

12352005

Hazard Statement

H302+H312+H332, H315, H319

Target

Factor Xa; Thrombin

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Purity

99.6

Solubility

10 mM in DMSO

Smiles

O=C(C1=NC2=C(CN(CC2)C)S1)N[C@H]3[C@H](CC[C@@H](C3)C(N(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)NC(C(NC4=CC=C(C=N4)Cl)=O)=O

Molecular Formula

C24H24D6ClN7O4S

Molecular Weight

554.09

Precautions

H302+H312+H332, H315, H319

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Furugohri T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep;6 (9) :1542-9.|[3]Mendell J, Lee F, Chen S, The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor. J Cardiovasc Pharmacol. 2013 Apr 23. [Epub ahead of print]|[4]Stacy ZA, et al. Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism. Cardiol Ther. 2016 Jun;5 (1) :1-18.